PROPEL Enrollment Ahead of Schedule with Completion Expected Q2 2008
WESTMINSTER, Colo., Sept. 24 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced the completion of
pre-planned interim analyses of patient response and safety data from the
Company's pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients
with relapsed or refractory peripheral T-cell lymphoma (PTCL). Results of
the interim analysis of patient response data exceeded the pre-specified
threshold for continuation of the trial, which required a minimum of four
responses (complete or partial) out of the first 35 evaluable patients, as
determined by independent oncology review. In addition, an independent Data
Monitoring Committee (DMC) completed an interim analysis of the safety data
from the first 35 evaluable patients and recommended that the trial
continue per the protocol. No major safety concerns were identified by the
DMC.
In accordance with the trial protocol, the DMC will conduct another
interim analysis of safety data from the first 65 evaluable patients. The
Company expects to report the outcome of the 65-patient safety analysis by
the end of 2007. Additionally, the Company now expects to complete
enrollment in the PROPEL trial in the second quarter of 2008.
"The outcomes of these interim analyses represent continued progress
toward the completion of the PROPEL trial and an important milestone in the
development of a potential new treatment option for patients with relapsed
or refractory peripheral T-cell lymphoma," said Pablo J. Cagnoni, M.D.,
Chief Medical Officer of Allos. "We are pleased with the progress of the
PROPEL trial and look forward to completing enrollment in the second
quarter of 2008."
PROPEL (Pralatrexate in Patients with Relapsed Or Refractory PEripheral
T- cell Lymphoma) is a pivotal Phase 2, international, multi-center,
open-label, single-arm study that will seek to enroll a minimum of 100
evaluable patients with relapsed or refractory PTCL who have progressed
after at least one prior treatment. Patients receive 30 mg/m2 of PDX once
every week for six weeks followed by one week of rest per cycle of
treatment. The primary endpoint of the study is objective response rate
(complete and partial response). Secondary endpoints include duration of
response, progression-free survival and overall survival. Owen O'Connor,
M.D., Ph.D., Director of the Lymphoid Development and Malignancy Program in
Columbia University Medical Center's Herbert Irving Comprehensive Cancer
Center and Chief of the Lymphoma Service at NewYork-Presbyterian Hospital,
is the international study chair. In July 2006, the Company reached
agreement with the United States Food and Drug Administration (FDA) under
its special protocol assessment (SPA) process on the design of this Phase 2
trial. The SPA process allows for FDA evaluation of a clinical trial
protocol intended to form the primary basis of an efficacy claim in support
of a New Drug Application (NDA), and provides an agreement that the study
design, including trial size, clinical endpoints and/or data analyses are
acceptable to the FDA. The FDA granted orphan drug designation to PDX for
treatment of T-cell lymphoma in July 2006 and granted fast track
designation to PDX for the treatment of patients with T-cell lymphoma in
September 2006. In April 2007, the Commission of the European Communities,
with a favorable opinion of the Committee for Orphan Medicinal Products of
the European Medicines Agency, or EMEA, granted orphan drug designation to
PDX for the treatment of patients with PTCL.
Information regarding this study is available at http://www.allos.com or the
U.S. government's clinical trials database at
http://www.clinicaltrials.gov.
About the Data Monitoring Committee (DMC)
The DMC is comprised of independent medical experts and was established
by Allos as part of the Company's compliance with good clinical practice
guidelines. The DMC is responsible for monitoring the on-going safety of
patients participating in the PROPEL trial and for conducting formal
interim safety assessments of trial results.
About Peripheral T-cell Lymphoma
Peripheral T-cell lymphomas, or PTCLs, are a biologically diverse and
uncommon group of blood cancers that account for approximately 10% to 15%
of all cases of non-Hodgkin's lymphoma, or about 7,100 patients annually.
The average five year survival rate for PTCL patients is approximately 25%.
There are currently no pharmaceutical agents approved for use in the
treatment of either first-line or relapsed or refractory PTCL.
About PDX (pralatrexate)
PDX is a novel, small molecule chemotherapeutic agent that inhibits
dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme
involved in the building of nucleic acid, or DNA, and other processes. PDX
was rationally designed for efficient transport into tumor cells via the
reduced folate carrier, or RFC-1, and effective intracellular drug
retention. The Company believes these biochemical features, together with
preclinical and clinical data in a variety of tumors, suggest that PDX may
have a favorable safety and efficacy profile relative to methotrexate and
certain other DHFR inhibitors.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on the
development and commercialization of small molecule therapeutics for the
treatment of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in a
pivotal Phase 2 trial in patients with relapsed or refractory peripheral
T-cell lymphoma. The Company is also investigating PDX in patients with
non-small cell lung cancer and a range of other lymphoma sub-types. The
Company's other product candidate is RH1, a targeted chemotherapeutic
agent, for which the company expects to initiate a Phase 1 trial in
patients with advanced solid tumors in the fourth quarter of 2007. For
additional information, please visit the Company's website at
http://www.allos.com.
Safe Harbor Statement
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
relating to the potential safety and efficacy profile of PDX relative to
methotrexate and certain other DHFR inhibitors, the potential safety and
efficacy of PDX for the treatment of PTCL or any other type of cancer; the
Company's projected timelines for conducting interim analyses and
completing enrollment in the PROPEL trial; and other statements that are
other than statements of historical facts. In some cases, you can identify
forward- looking statements by terminology such as "may," "will," "should,"
"expects," "intends," "plans," anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "continue," and other similar
terminology or the negative of these terms, but their absence does not mean
that a particular statement is not forward-looking. Such forward-looking
statements are not guarantees of future performance and are subject to
risks and uncertainties that may cause actual results to differ materially
from those anticipated by the forward-looking statements. These risks and
uncertainties include, among others: that the Company may experience delays
in the conduct or completion of the PROPEL trial, whether caused by
competition, adverse events, patient enrollment rates, regulatory issues or
other factors; that clinical trials may not demonstrate that PDX is both
safe and effective for the treatment of patients with PTCL or any other
type of cancer; that data from preclinical studies and clinical trials may
not be indicative of future clinical trial results; that the safety and/or
efficacy results of the PROPEL trial may not support an application for
marketing approval in the United States or any other country; that an
application for marketing approval may not be accepted for priority review
or at all by the FDA or any other regulatory authority; and that the
Company may lack the financial resources and access to capital to fund
future clinical trials for PDX or any of its other product candidates.
Additional information concerning these and other factors that may cause
actual results to differ materially from those anticipated in the forward-
looking statements is contained in the "Risk Factors" section of the
Company's Annual Report on Form 10-K for the year ended December 31, 2006
and in the Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press release.
All forward- looking statements are based on information currently
available to the Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to reflect
events or circumstances after the date of this presentation, except as
required by law.
Note: The Allos logo is a trademark of Allos Therapeutics, Inc.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com/
CONTACT:
Derek Cole, Vice President, Investor
Relations of Allos Therapeutics, Inc., +1-720-540-5367,
dcole@allos.com
|
